- Investor's Business Daily•12 hours ago
Regeneron expects to top Amgen's recent heart-drug study in a team-up with Sanofi.
- Financial Times•yesterday
Half a million middle-aged Britons will have their DNA decoded in a £120m collaboration between the public sector research facility UK Biobank and two pharmaceutical companies, GlaxoSmithKline and Regeneron. ...
Britain's GlaxoSmithKline and U.S.-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease. By analysing genetic variations and health in 500,000 middle-aged and older Britons, the partners said on Thursday they hoped to identify promising leads for new medicines. The aim is to analyse DNA from an initial 50,000 samples by the end of 2017, using Regeneron's large gene sequencing centre in New York.
REGN : Summary for Regeneron Pharmaceuticals, Inc. - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||361.50 x 100|
|Ask||370.90 x 100|
|Day's Range||364.44 - 370.58|
|52 Week Range||325.35 - 452.96|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||47.41|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|